determined during Placebo: −0.5 screening (−0.6, −0.4) No relative difference on a 4 point scale (95% CI 0.2, −0.1, p=0.36) Authors’ conclusion: healthy peri- and postmenopausal sedentary women, 12 weeks of omega-3 treatment compared with placebo “Among did not improve VMS frequency, VMS bother, sleep, or mood compared to placebo.” Sternfeld et al (2014)16, physical interventions (exercise) MsFLASH 02 - Late-peri and Exercise (aerobic Usual activity Vasomotor VMS frequency at (1) Yes** N = 248 exercise training 3 symptoms 12 weeks from (2) Yes** Age = 40-62 sedentary women times/week for 12 frequency and (3) Yes** baseline, mean Duration = 12 with frequent weeks) bother (95% CI) (4) Yes** weeks vasomotor (5) Yes** Follow-up = at 8 or symptoms (VMS) Exercise: EB risk of bias: −2.4/day, 12 weeks (−3.0, Low −1.7) activity: −2.6 Difference: 0.2 (−0.6, 1.1) VMS bother at 12 weeks from baseline, mean (95% CI) Exercise: (−0.6, −0.5 −0.4) Usual activity: −0.5 (−0.6, −0.4) Difference: 0.0 (−0.1, 0.2)
determined during screening Placebo: −0.5 (−0.6, −0.4) No relative difference on a 4 point scale (95% CI −0.1, 0.2, p=0.36) Authors’ conclusion: “Among healthy peri- and postmenopausal sedentary women, 12 weeks of omega-3 treatment compared with placebo did not improve VMS frequency, VMS bother, sleep, or mood compared to placebo.” Sternfeld et al (2014)16, physical interventions (exercise) MsFLASH 02 - N = 248 Age = 40-62 Duration = 12 weeks Follow-up = at 8 or 12 weeks Late-peri and sedentary women with frequent vasomotor symptoms (VMS) Exercise (aerobic exercise training 3 times/week for 12 weeks) Usual activity Vasomotor symptoms frequency and bother VMS frequency at 12 weeks from baseline, mean (95% CI) Exercise: −2.4/day, (−3.0, −1.7) activity: −2.6 Difference: 0.2 (−0.6, 1.1) VMS bother at 12 weeks from baseline, mean (95% CI) Exercise: −0.5 (−0.6, −0.4) Usual activity: −0.5 (−0.6, −0.4) Difference: 0.0 (−0.1, 0.2) (1) Yes** (2) Yes** (3) Yes** (4) Yes** (5) Yes** EB risk of bias: Low